Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations

研究激活 HER2 突变的 ER 转移性乳腺癌的生物学和治疗脆弱性

基本信息

  • 批准号:
    10624281
  • 负责人:
  • 金额:
    $ 18.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract The candidate, Ms. Utthara Nayar, PhD, is a translational cancer biologist, and currently a Research Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute of MIT and Harvard. She employs genomic technology to investigate mechanisms of resistance in estrogen receptor- expressing (ER+) metastatic breast cancer (MBC). Prior to this, she trained in viral oncology laboratories at Cornell University and Brigham and Women's Hospital. She expects to pursue an academic career at the intersection of basic and translational research in breast cancer that will involve molecular and genomic approaches, in collaboration with physician-scientists and computational biologists working to end the disease. This proposal lays out a structured 3-year plan of research and coursework, including the acquisition of data science, grant-writing, and translational skills, which will uniquely situate the investigator as an experienced experimental biologist and bioinformatician. The research project proposed, in combination with the team of collaborators and institutional environment, is designed to position her on a road to independence within the field of therapeutic response and resistance in breast cancer. The primary reason for breast cancer mortality is the development of resistance, through largely unknown mechanisms, to targeted anti-estrogen therapies in ER+ MBC. Dr. Nayar recently identified acquired activating mutations in human epidermal growth factor receptor 2 (HER2), which activates the MAPK pathway, in patients with resistance, and demonstrated that these directly conferred resistance to anti-ER agents. Since this is an emerging class of resistance, a deeper understanding of the biology and therapeutic vulnerabilities of tumors bearing such mutations or related genetic alterations in the MAPK pathway is required. The scientific objective of this proposal is to study the effect of MAPK signaling from HER2 mutations in ER+ MBC in terms of two major biological consequences that Dr. Nayar identified through global transcriptomic analysis in ER+ HER2- mutant tumors: altered ER pathway, and enhanced interferon and inflammatory signaling. This application proposes to investigate these questions in two distinct aims. In specific Aim 1, the effect of HER2 mutations on the ER-associated and global transcriptional network will be examined using genome-scale in vitro approaches (ChIP-seq/ATAC-seq). Aim 2 determines the implication of enhanced inflammatory signaling in ER+ HER2- mutant tumors, by ascertaining the autocrine and paracrine effects on signaling and immunogenicity in cell line and mouse model systems, as well as by examining tumor immune microenvironment in patient tumor samples. At the end of the project, we can expect to gain a deeper understanding of HER2-mutant and related breast tumors in terms of the effect of MAPK activation on ER signaling and immunogenicity, as well as their potential for targetability by epigenetic (Aim 1) or immunotherapeutic (Aim 2) approaches.
项目 总结/摘要 候选人Utthara Nayar女士,博士,是一位翻译癌症生物学家,目前是美国癌症研究所的研究员。 医学在达纳法伯癌症研究所,哈佛医学院,和麻省理工学院的布罗德研究所, 哈佛。她采用基因组技术研究雌激素受体的耐药机制- 表达(ER+)转移性乳腺癌(MBC)。在此之前,她在病毒肿瘤学实验室接受了培训, 康奈尔大学和布里格姆妇女医院她希望在大学里从事学术事业, 乳腺癌基础和转化研究的交叉,将涉及分子和基因组 方法,与医生科学家和计算生物学家合作,致力于结束这种疾病。 该提案列出了一个结构化的3年研究和课程计划,包括数据的获取 科学,赠款写作和翻译技能,这将独特地使研究者成为经验丰富的研究者。 实验生物学家和生物信息学家。该研究项目提出,结合团队的 合作者和机构环境,旨在使她走上独立的道路, 乳腺癌的治疗反应和耐药性领域。 乳腺癌死亡率的主要原因是耐药性的发展, 机制,ER+ MBC中的靶向抗雌激素治疗。纳亚尔博士最近发现获得性激活 患者中激活MAPK通路的人表皮生长因子受体2(HER 2)突变 具有抗性,并证明这些直接赋予对抗ER剂的抗性。由于这是一个 新出现的耐药性,对肿瘤生物学和治疗弱点的更深入了解 需要在MAPK途径中携带这种突变或相关的遗传改变。科学目标 该建议的一个目的是研究ER+ MBC中HER 2突变的MAPK信号传导的作用, Nayar博士通过ER+ HER 2的全球转录组学分析确定的主要生物学后果- 突变型肿瘤:ER通路改变,干扰素和炎症信号增强。本申请 建议在两个不同的目的调查这些问题。在具体目标1中,HER 2突变对 ER相关的和全局的转录网络将使用基因组规模的体外方法进行研究 (ChIP-seq/ATAC-seq)。目的2确定增强的炎症信号传导在ER+ HER 2 - 1中的意义。 突变型肿瘤,通过确定细胞系中自分泌和旁分泌对信号传导和免疫原性的影响, 和小鼠模型系统,以及通过检查患者肿瘤中的肿瘤免疫微环境, 样品在项目结束时,我们可以期望获得更深入的理解HER 2突变体和相关的 乳腺肿瘤的MAPK激活对ER信号传导和免疫原性的影响,以及它们的 通过表观遗传学(Aim 1)或免疫学(Aim 2)方法的靶向潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Utthara Nayar其他文献

Utthara Nayar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Utthara Nayar', 18)}}的其他基金

Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations
研究激活 HER2 突变的 ER 转移性乳腺癌的生物学和治疗脆弱性
  • 批准号:
    9977376
  • 财政年份:
    2021
  • 资助金额:
    $ 18.89万
  • 项目类别:
Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations
研究激活 HER2 突变的 ER 转移性乳腺癌的生物学和治疗脆弱性
  • 批准号:
    10412908
  • 财政年份:
    2021
  • 资助金额:
    $ 18.89万
  • 项目类别:

相似海外基金

Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer
激素受体阳性乳腺癌对抗雌激素治疗的耐药性
  • 批准号:
    7515253
  • 财政年份:
    2008
  • 资助金额:
    $ 18.89万
  • 项目类别:
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer
激素受体阳性乳腺癌对抗雌激素治疗的耐药性
  • 批准号:
    7847493
  • 财政年份:
  • 资助金额:
    $ 18.89万
  • 项目类别:
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer
激素受体阳性乳腺癌对抗雌激素治疗的耐药性
  • 批准号:
    8270581
  • 财政年份:
  • 资助金额:
    $ 18.89万
  • 项目类别:
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer
激素受体阳性乳腺癌对抗雌激素治疗的耐药性
  • 批准号:
    8182319
  • 财政年份:
  • 资助金额:
    $ 18.89万
  • 项目类别:
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer
激素受体阳性乳腺癌对抗雌激素治疗的耐药性
  • 批准号:
    8376834
  • 财政年份:
  • 资助金额:
    $ 18.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了